Treatment of Sjogren's syndrome by administration of TR18...

Details Treatment of Sjogren's syndrome by administration of TR18... Treatment of Sjogren's syndrome by administration of TR18...

2008-05-13

2008-05-13

O'Hara, Eileen B. (Department: 1646)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Fusion protein or fusion polypeptide

C424S185100, C514S012200, C514S008100, C530S350000, C530S402000

Reexamination Certificate

active

07371388

ABSTRACT:
The present invention relates to TR18 polypeptides. In particular, isolated nucleic acid molecules are provided encoding human TR18 protein. TR18 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of TR18 activity. The invention further relates to methods of treating, preventing, prognosing, or diagnosing an autoimmune disease or condition associated with an autoimmune disease, comprising administering to a patient an effective amount of polypeptides of the invention.

REFERENCES:
patent: WO-00/40716 (2000-07-01), None
patent: WO-00/40716 (2000-07-01), None
patent: WO-00/50633 (2000-08-01), None
patent: WO-00/68378 (2000-11-01), None
patent: WO-01/12812 (2001-02-01), None
patent: WO-01/24811 (2001-04-01), None
patent: WO-01/60397 (2001-08-01), None
patent: WO-01/75067 (2001-10-01), None
patent: WO-01/75067 (2001-10-01), None
patent: WO-01/87979 (2001-11-01), None
Marsters et al., Current Biology, vol. 10, pp. 785-788, Jun. 16, 2000.
Laabi et al., Genbank Accession No. NP—00183, (Oct. 31, 2000).
Carninci et al., Genbank Accession No. NP—035738, (Jan. 7, 2002).
Laabi et al., Genbank Accession No. S43486, (Jan. 27, 1995).
Tsapis, A., Genbank Accession No. Z14954, (Jul. 22, 1994).
Laabi et al., Genbank Accession No. Z29575, (Jun. 13, 1994).
Tsapis, A., Genbank Accession No. Z14955, (Jul. 26, 1993).
Laabi et al., Genbank Accession No. Z29574, (Jun. 25, 1997).
Laabi et al., Genbank Accession No. Z29572, (Jun. 13, 1994).
Birren et al., Genbank Accession No. AC034281, (Apr. 5, 2000).
Mahairas et al., Genbank Accession No. AQ182725, (Sep. 9, 1998).
Loftus et al., Genbank Accession No. U95742, (Jan. 10, 2000).
Bruce et al., Genbank Accession No. AC007216, (Jan. 28, 2000).
Marra et al., Genbank Accession No. AA989895, (Jun. 2, 1998).
Wintero et al., Genbank Accession No. Z81277, (Oct. 24, 1996).
Bonaldo et al., Genbank Accession No. AI044213, (Feb. 11, 1999).
Laabi et al., Genbank Accession No. NM—001192, (Mar. 24, 1999).
NCI-CGAP, Genbank Accession No. AA286974, (Aug. 15, 1997).
NCI-CGAP, Genbank Accession No. AW139591, (Oct. 30, 1999).
NCI-CGAP, Genbank Accession No. AA258846, (Aug. 13, 1997).
NCI-CGAP, Genbank Accession No. AI865358, (Dec. 21, 1999).
NCI-CGAP, Genbank Accession No. AA286871, (Aug. 14, 1997).
NCI-CGAP, Genbank Accession No. AA633372, (Oct. 28, 1997).
NCI-CGAP, Genbank Accession No. AA259026, (Aug. 13, 1997).
NCI-CGAP, Genbank Accession No. AA743176, (Jan. 27, 1998).
NCI-CGAP, Genbank Accession No. AA987627, (Jul. 27, 1998).
Laabi et al., Nucleic Acid Research, vol. 22, No. 7, pp. 1147-1154, 1994.
Locksley et al., “The TNF and TNF Receptor Superfamilies: Integrating Mammalian Biology,” Cell, vol. 104, pp. 487-501, Feb. 2001.
Berkow, R. et al. (eds.), “The Merck Manual of Diagnosis and Therapy, (Fifteenth Edition),” Merck & Co., Inc., NJ, at pp. 319 to 322 (1987).
Berkow, R. et al. (eds.), “The Merck Manual of Diagnosis and Therapy, (Fifteenth Edition),” Merck & Co., Inc., NJ, at pp. 1249 to 1250 (1987).
GenBank Accession No. NP—006564, (Oct. 7, 2002).
Ebner et al., Geneseq Database Accession No. AAW58391, (May 7, 1998).
Groom et al., “Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjögren's syndrome,” J. Clin. Invest. (2002) 109:59-68.
Mariette et al., “The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjögren's syndrome,” Ann. Rheum. Dis. (2002) 62:168-171.
Thompson et al., “BAFF Binds to the Tumor Necrosis Factor Receptor-like Molecule B Cell Maturation Antigen and Is Important for Maintaining the Peripheral B Cell Population,”J. Exp. Med., 192(1):129-135 (Jul. 3, 2000).
Gross et al., “TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease,”Nature, 404(6781):995-999 (Apr. 27, 2000).

Affiliated with

Also associated with

Rating

Treatment of Sjogren's syndrome by administration of TR18... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Treatment of Sjogren's syndrome by administration of TR18..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of Sjogren's syndrome by administration of TR18... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2757013